Data from this ex vivo assay were consistent with the observation in the CT26 syngeneic mouse colonic tumor model, in which an enhanced antitumor activity was observed in the combination treatment group (SAR’245 plus anti-PD-1 antibody) compared with the single-agent treatment (Ma and colleagues; submitted for publication). The gene discussed is PDCD1; the disease is colonic neoplasm.